Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol: Pembrolizumab in combination with gemcitabine and cisplatin for patients with advanced biliary tract cancer
Study: Phase III, double-blind, randomized, controlled, multicenter, open-label trial (KEYNOTE-966) Previously untreated, unresectable, locally advanced or metastatic biliary tract cancer Pembrolizumab + Gemcitabine + Cisplatin (n=533) vs. Gemcitabine + Cisplatin
New Protocol: Ibrutinib and rituximab for patients with previously untreated chronic lymphocytic leukemia (CLL)
Study: Phase III, randomized,controlled, multicenter, open-label trial (FLAIR) Treatment naive CLL–small lymphocytic lymphoma (SLL) İbrutinib + Rituximab (n=386) vs. FCR (n=385) Efficacy: mPFS: NR vs. 67 mos, p
New Protocol: Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Study: Phase III, randomized, open-label trial (SUNLIGHT) Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer Trifluridine–tipiracil (FTD–TPI) + Bevacizumab
New indication: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Study: Multicenter, open-label, phase 1/2 trial Cisplatin ineligible, local advanced/metastatic urothelial carcinoma Enfortumab vedotin + pembrolizumab q21 (n=45) Efficacy: CRR: 15.6% [7 of 45 pts] ORR: 73.3% [33 of 45
New Protocol: Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (CRPC)
Study: Phase III, randomized, double-blind, placebo-controlled, multicenter (MAGNITUDE) Treatment naïve, Homologous Recombination Repair positive (HRR+) mCRPC Niraparib + Abiraterone acetate + prednizon (Niraparib + AAP group, n=212) vs. PBO +
New Protocol: Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
Study: Open-label, single-arm, phase 2 study Pretreated metastatic or recurrent ACC Axitinib + Avelumab q28 (n=28) Efficacy: ORR: 21% [8.3%-41.0%] mPFS: 7.3 mos [3.7-11.2 mos] mOS: 16.6 mos [12.4-NR] Safety:
New Protocol: Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia
Study: Prospectively Randomized , phase 3 trial Treatment naïve Waldenström’s macroglobulinemia (WM) Bortezomib, dexamethasone, rituximab, and cyclophosphamide (B-DRC ) vs. DRC Efficacy: 24 mos PFS: 80.6 vs 72.8 %, p=0.320
New Indication: Tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer ( POSEIDON)
Study: Phase III, randomized, three-arm, open-label study Previously untreated mNSCLC Arm A: (T+C+CT) Tremelimumab 75 mg plus durvalumab 1,500 mg and chemotherapy for up to four 21-day cycles, followed by
New Drug: Futibatinib for cholangiocarcinoma
Study: A single-arm, multicenter, phase 2 study Advanced/metastatic unresectable iCCA harboring FGFR2 gene fusions Disease progression after ≥1 line of systemic therapy Futibatinib 20 mg QD until disease progression/unacceptable toxicity
New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)
Study: Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154)) Efficacy: mOS : 21.9 vs. 13.0 mos
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study: Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1) zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1)
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Protocol: Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia
Study: Two-stage, single-arm, phase 2 trial Previously untreated de novo acute myeloid leukaemia IV daunorubicin (60 mg/m2 on days 1-3), IV cytarabine (100 mg/m2 on days 1-7), and oral venetoclax
New Protocol: Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer
Study: Open-label, randomised, phase 3 study (PEACE-1) De novo metastatic prostate adenocarcinoma Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m2 once every 3 weeks, N:296),
New Protocol: Darolutamide in Metastatic, Hormone-Sensitive Prostate Cancer
Study: International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and docetaxel. Efficacy: Median treatment duration: 41 m vs 16.7 months